subject: Biogen Idec Inc.: Pharmavitae Profile - Market Research Report On Aarkstore Enterprise [print this page] Introduction Introduction
This analysis examines the historical and forecast performance for Biogen Idec in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits
Gain insight into Biogen Idecs strategic outlook across the next 6 years
Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
Highlights
Strategic insight into the prospects for Biogen Idec over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the companys prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered
Benchmark Biogen Idecs performance against key rivals in the prescription pharmaceutical sector
See how the launch of companys multiple sclerosis portfolio is in transition as oral treatments become available
Table of Contents :
ABOUT DATAMONITOR HEALTHCARE 2
About the PharmaVitae team 2
Chapter 1 About this profile 3
PharmaVitae Explorer database 3
Chapter structure 3
Data sourcing 4
Chapter 2 Executive summary 5
Key findings 5
Prescription pharmaceutical sales and growth rate performance, 200315 6
Financial performance, 200315 7
Biogen Idec: PharmaVitae forecasts at a glance 8
Strategic insight 9
SWOT analysis 14
Chapter 3 Quarterly news update 21
Latest quarterly sales 21
Latest comment 21
Latest prescription pharma product news 25
Latest corporate news 29
Future product milestones 32
Chapter 4 Company introduction 33
Key findings 33
Background 34
M&A history 34
Current corporate structure 37
Chapter 5 Company sales 39
Key findings 39
Prescription pharmaceutical sales and growth rate analysis, 200315 40
Product analysis 41
Therapy area analysis 49
Geographic analysis 51
Launch/core/expiry analysis 54
Molecule type analysis 59
Externalization analysis 62
Chapter 6 Company financials 64
Key findings 64
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 200309 65
